{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-011184","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.169318+00:00","generated_at":"2026-06-19T23:52:55.601214+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Collegium prelim Q4/FY22 revenue at high-end of guidance; announces $175M convertible notes offering","bullets":["Prelim FY22 product revenue $460.0M-$462.5M; Q4 $125.7M-$128.2M; both at or above prior guidance high-end.","Prelim FY22 adjusted EBITDA $261.5M-$264.0M; Q4 adjusted EBITDA $71.9M-$74.4M.","Announced $175M convertible senior notes due 2029, with $26.25M greenshoe option to initial purchaser.","Intends to use part of proceeds to repurchase portion of its 2.625% 2026 convertible notes in private transactions.","Remaining proceeds for general corporate purposes including business development, debt repayment, and shareholder returns."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-011184","json":"https://secwatch.observer/filing/0001104659-23-011184.json","markdown":"https://secwatch.observer/filing/0001104659-23-011184.md","text":"https://secwatch.observer/filing/0001104659-23-011184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/0001104659-23-011184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/tm235588d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T23:52:55.601214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00c1d51e155d94da33e7283680ad6441f49ed37e","claim":"COLLEGIUM PHARMACEUTICAL, INC reported the fiscal year ended December 31, 2022 results: revenue $460.0 million to $462.5 million.","evidence_excerpt":"For the fiscal year ended December 31, 2022, we currently estimate: o Product revenues in the range of $460.0 million to $462.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/0001104659-23-011184-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$460.0 million to $462.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"02b69c3c39817bf6a45e50dcd14fa14b91b65764","claim":"COLLEGIUM PHARMACEUTICAL, INC reported the fourth quarter ended December 31, 2022 results: revenue $125.7 million to $128.2 million.","evidence_excerpt":"For the fourth quarter ended December 31, 2022, we currently estimate: o Product revenues in the range of $125.7 million to $128.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/0001104659-23-011184-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$125.7 million to $128.2 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}